Rituximab and ocrelizumab go head to head in randomized trial ...

Multiple sclerosis (MS) can have a substantial impact on many aspects of life beyond physical health, with 51% of people ...

A Norwegian-Swedish clinical trial published in the New England Journal of Medicine demonstrates that rituximab, a low-cost B ...

The Anne Arundel County resident recently announced his retirement because of complications surrounding a multiple sclerosis ...

Multiple sclerosis (MS) can have a substantial impact on many aspects of life beyond physical health, with 51% of people ...

Increasing the Ocrevus dose used in treating MS provided no additional benefit versus the approved regimen in trials with over 1,500 patients.

Multiple sclerosis occurs when a person’s immune system is triggered to attack the myelin sheath—a protective coating surrounding nerve cells in the central nervous system (CNS). The CNS is made up of ...

Sponsored by Novartis Jamie Lynn Sigler opens up about self-advocacy, finding her treatment plan and why your voice should be the loudest in the room when it comes to your health.

Sanofi said it received European Union approval for Cenrifki, a new multiple sclerosis medicine, after U.S. regulators ...

A Norwegian Swedish clinical trial published in the New England Journal of Medicine (NEJM) demonstrates that rituximab, a low ...